Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1997040838 - NOUVELLE UTILISATION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. Use of an SQDG having the formula

CHjOR1

R2OCH (I)

CH20 - deoxyhexose - S03"

wherein R1 and R2 , which are the same or different, are hydrogen or saturated or unsaturated, optionally hydroxy-substituted acyl groups, protonated or as a salt, for the preparation of a pharmaceutical composition for the treatment of inflammatory skin diseases or disorders.

2. Use according to claim 1 of a sulphoquinovosyldiacylglycerol , an SQDG having the formula


CH20 - quinovose - S03~

wherein R1 and R2, which are the same or different, are hydrogen, acetyl or acyl groups comprising 14-22 carbon atoms, preferably 16-18, and having up to 6 unsaturations, preferably 0-3.

3. Use according to claim 1 or 2 of a 1, 2-0,0-dipalmitoyl-[β'-sulpho-α-D-quinovopyranosyl (l'→3) ]-sn-glycerol, an SQDG having the formula

CH2OCO(CH2)14CH3

CH3(CH2)14COOCH (III)
I

CH20 - quinovose - S03 protonated or as a salt.

4. Use according to any of claims 1-3 of an SQDG for the prophylaxis or treatment of atopic dermatitis, urticaria or psoriasis.

5. Use according to any of claims 1-3 of an SQDG as an antiproliferative agent.

6. Use according to any of claims 1-3 of an SQDG for the prophylaxis or treatment of psoriasis.

7. Use according to any of claims 1-3 of an SQDG in
combination with a polyunsaturated fatty acid for the prophylaxis or treatment of psoriasis.

8. Use according to claim 7 of an SQDG in combination with linoleic acid or linolenic acid.

9. Pharmaceutical composition comprising an SQDG having the formula

CHo0RJ

R20CH (I)

CH20 - deoxyhexose - S03~

wherein R1 and R2 , which are the same or different, are hydrogen or saturated or unsaturated, optionally hydroxy-substituted acyl groups, protonated or as a salt, in combination with a polyunsaturated fatty acid and a therapeutically acceptable carrier.

10. Pharmaceutical composition according to claim 9, comprising an SQDG having the formula O^OR1

R2OCH (II)
I CH2° ~ quinovose - S03~

wherein R1 and R2, which are the same or different, are hydrogen, acetyl or acyl groups comprising 14-22 carbon atoms, preferably 16-18, and having up to 6 unsaturations, preferably 0-3 , and a polyunsaturated fatty acid from the n-3 family for the treatment of psoriasis.

11. Pharmaceutical composition according to claim 9,
comprising an SQDG having the formula

C^OR1

R2OCH (II)
I CH20 - quinovose - S03

wherein R1 and R2 , which are the same or different, are hydrogen, acetyl or acyl groups comprising 14-22 carbon atoms, preferably 16-18, and having up to 6 unsaturations, preferably 0-3, and a polyunsaturated fatty acid from the n-6 family for the treatment of atopic dermatitis.

12. Pharmaceutical composition according to any of claims 9-11, comprising a 1, 2-0,0-dipalmitoyl-[6/-sulpho-α-D-quinovopyranosyl(l'-O) ] -sn-glycerol, an SQDG having the formula

CH2OCO(CH2) 14CH3

CH3(CH2)14CO .OC IH (III)

CH20 - quinovose - S03~

protonated or as a salt.

13. Pharmaceutical composition according to any of claims 9-12 for oral, topical, rectal, enteral or parenteral administration.

14. A new PAF-receptor antagonist, characterized in being an SQDG having the formula

C^OR1

R20CH (I)

CH20 - deoxyhexose - S03

wherein R1 and R2 , which are the same or different, are hydrogen or saturated or unsaturated, optionally hydroxy-substituted acyl groups, protonated or as a salt.